Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease
RM Dutescu, QX Li, J Crowston, CL Masters… - Graefe's Archive for …, 2009 - Springer
RM Dutescu, QX Li, J Crowston, CL Masters, PN Baird, JG Culvenor
Graefe's Archive for Clinical and Experimental Ophthalmology, 2009•SpringerBackground Retinal ganglion cell loss is considered to be a cause of visual impairment in
Alzheimers patients. Alterations in amyloid precursor protein (APP) processing and amyloid-
β (Aβ) accumulation, key molecules associated with Alzheimers disease pathogenesis, may
therefore contribute to retinal damage. We therefore investigated retinal APP processing and
eye morphology in Alzheimers transgenic mouse models. Methods Eyes and brain samples
of 2-to 18-month-old transgenic mice expressing human APP with the double Swedish …
Alzheimers patients. Alterations in amyloid precursor protein (APP) processing and amyloid-
β (Aβ) accumulation, key molecules associated with Alzheimers disease pathogenesis, may
therefore contribute to retinal damage. We therefore investigated retinal APP processing and
eye morphology in Alzheimers transgenic mouse models. Methods Eyes and brain samples
of 2-to 18-month-old transgenic mice expressing human APP with the double Swedish …
Background
Retinal ganglion cell loss is considered to be a cause of visual impairment in Alzheimer`s patients. Alterations in amyloid precursor protein (APP) processing and amyloid-β (Aβ) accumulation, key molecules associated with Alzheimer`s disease pathogenesis, may therefore contribute to retinal damage. We therefore investigated retinal APP processing and eye morphology in Alzheimer`s transgenic mouse models.
Methods
Eyes and brain samples of 2- to 18-month-old transgenic mice expressing human APP with the double Swedish mutation (APPswe) (APP K595N/M596L)(Tg2576) were compared with eyes and brain tissue from wild-type background C57BL6xSJL controls. In addition, 6- to 12-month-old double transgenic mice over-expressing human APPswe and mutant presenilin 1 with exon 9 deletion (APPswe/PS1-dE9) were compared with background controls of C57BL6xC3H strain. Tissue samples were fixed in formalin for immunohistochemistry, and dissected retinal and cerebellar extracts were frozen for Western blotting and enzyme-linked immunosorbent assay (ELISA). Monoclonal antibodies 1E8 and WO2 were used for immunohistochemical detection of APP and Aβ, whereas Aβ 42/40 levels were assayed by ELISA. APP and processed fragments were detected biochemically by Western blotting with domain-specific antibodies, using antibody WO2 (Aβ) and rabbit antibody 369 to the C-terminal domain of APP.
Results
Immunocytochemistry revealed strong cytoplasmic expression of APP and possibly Aβ in retinal ganglion cells and inner nuclear layer cells, and in lens and corneal epithelia for APP transgenic mice. Retinas from the APP transgenic mouse strains contained 18 to 70 kDa APP proteolytic products that were not detected in the cerebellum. We found a higher proportion of APP α-secretase generated C-terminal fragments in transgenic retinal tissues than β-secretase-generated C-terminal fragments. Very low level Aβ was detected in transgenic retinas by ELISA; retinal Aβ 42 was 75 times less than for transgenic brain. Aβ was not detected in mouse retina by Western blotting in our study, indicating much less generation of Aβ in retina than brain tissue.
Conclusions
Alzheimer’s mouse model retinas present with different APP proteolytic products and have a significantly lower production of amyloidogenic Aβ than found in brain.
Springer